Regeneron Pharmaceuticals’ (REGN) “Sell” Rating Reaffirmed at Chardan Capital
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “sell” rating reissued by stock analysts at Chardan Capital in a research report issued on Friday. They currently have a $325.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s price objective suggests a potential downside of 20.02% from the stock’s previous close.
The analysts wrote, “We believe the news is an important long-term negative, as REGN (Sell, PT$325) is increasingly exposed to what we expect could be a 2017+ theme in wet AMD of treatment burden reduction.””
Several other equities analysts have also commented on the stock. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $521.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday. Jefferies Group reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 17th. Vetr lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $419.76 target price on the stock. in a report on Monday, July 11th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 target price on the stock in a report on Tuesday, August 9th. Finally, Leerink Swann restated a “buy” rating and issued a $530.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, September 21st. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and an average price target of $472.46.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.83% during midday trading on Friday, reaching $398.92. 419,895 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52-week low of $329.09 and a 52-week high of $592.59. The stock has a 50-day moving average price of $405.49 and a 200-day moving average price of $390.67. The stock has a market cap of $41.74 billion, a P/E ratio of 62.23 and a beta of 1.24.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period last year, the firm earned $2.89 EPS. The business’s quarterly revenue was up 21.4% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals will post $11.00 earnings per share for the current year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the sale, the director now owns 15,125 shares in the company, valued at approximately $6,428,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.40% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares during the period. Winslow Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $291,760,000. FMR LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares during the period. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares during the period. Finally, Emerald Acquisition Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $87,319,000. Institutional investors and hedge funds own 68.16% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.